Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability. The company also ...

Labcorp’s Q4 results came in below Wall Street’s revenue expectations, leading to a negative market reaction, while ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors rule out the disease in people 55 and older with symptoms of cognitive ...

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...

The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.

Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary ...

Labcorp Holdings Inc. (NYSE:LH) Q4 2025 Earnings Call Transcript February 17, 2026 Labcorp Holdings Inc. misses on earnings expectations. Reported EPS is $1.98 EPS, expectations were $3.95. Operator: ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) missed Wall Street’s revenue expectations in Q4 CY2025, but sales ...

Competitive dynamics loom large. Quest Diagnostics recently delivered 7.1% year-over-year revenue growth, beating estimates by 1.9%, with shares rallying 9.4% following results. That strong showing ...